LRMR

Larimar Therapeutics, Inc. Common Stock

3.87

USD

+0.05

+1.18%

Sep 23, 16:00 UTC -4

Closed

After-Market

3.79

-0.07

-1.89%

LRMR Earnings Reports

Positive Surprise Ratio

LRMR beat 27 of 40 last estimates.

68%

Next Report

Date of Next Report

Nov 03, 2026

Estimate for Q3 26 (Revenue/ EPS)

-$0.35

Implied change from Q2 26 (Revenue/ EPS)

+16.67%

Implied change from Q3 25 (Revenue/ EPS)

-42.62%

Larimar Therapeutics, Inc. Common Stock earnings per share and revenue

On Aug 04, 2026, LRMR reported earnings of -0.30 USD per share (EPS) for Q2 26, beating the estimate of -0.38 USD, resulting in a 22.84% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -0.95% price change (close before vs. close after earnings).

Looking ahead to Q3 26, 10 analysts forecast an EPS of -0.35 USD, with revenue projected to reach -- USD, implying an increase of 16.67% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Champions Oncology, Inc.

Report Date

Sep 10, 2026 For Q1 27

Estimate

-$0.01

Actual

-$0.03

Surprise

-194.12%

PharmaCyte Biotech, Inc. Common Stock

Report Date

Sep 14, 2026 For Q1 27

Estimate

Actual

-$0.54

Surprise

FAQ

What were Larimar Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?

For Q2 2026, Larimar Therapeutics, Inc. Common Stock reported EPS of -$0.30, beating estimates by 22.84%, and revenue of $0.00, 0% as expectations.

How did the market react to Larimar Therapeutics, Inc. Common Stock's Q2 2026 earnings?

The stock price moved down -0.95%, changed from $4.20 before the earnings release to $4.16 the day after.

When is Larimar Therapeutics, Inc. Common Stock expected to report next?

The next earning report is scheduled for Nov 03, 2026.

What are the forecasts for Larimar Therapeutics, Inc. Common Stock's next earnings report?

Based on 10 analysts, Larimar Therapeutics, Inc. Common Stock is expected to report EPS of -$0.35 and revenue of -- for Q3 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.